Synlogic Inc (NAS:SYBX)

$ 1.77 0.05 (2.91%) Market Cap: 20.58 Mil Enterprise Value: -10.47 Mil PE Ratio: 0 PB Ratio: 0.38 GF Score: 45/100

Synlogic Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Synlogic Inc at Virtual Investor Conferences Transcript
Mar 09, 2023
Synlogic Inc To Announces Proof of Concept for SYNB8802 in Enteric Hyperoxaluria call Transcript
Dec 15, 2022
Synlogic Inc Phase 2 Announcement Call Transcript
Oct 18, 2022
Q2 2022 Synlogic Inc Earnings Call Transcript
Aug 11, 2022

$16.35 (+11.22%)

Earnings
Synlogic Inc at Chardan Leadership Call Transcript
Jun 07, 2022
Q1 2022 Synlogic Inc Earnings Call Transcript
May 12, 2022

$16.05 (-14.40%)

Earnings
Q4 2021 Synlogic Inc Earnings Call Transcript
Mar 17, 2022

$30.6 (-4.67%)

Earnings
Q3 2021 Synlogic Inc Earnings Call Transcript
Nov 10, 2021

$39.9 (-1.12%)

Earnings
Synlogic Inc Clinical Program Update Call Transcript
Sep 20, 2021
Q2 2021 Synlogic Inc Earnings Call Transcript
Aug 12, 2021

$43.05 (-1.71%)

Earnings
Synlogic Inc Annual Shareholders Meeting Transcript
Jun 10, 2021
Q1 2021 Synlogic Inc Earnings Call Transcript
May 13, 2021

$47.4 (-3.07%)

Earnings
Q4 2020 Synlogic Inc Earnings Call Transcript
Mar 25, 2021

$58.95 (+1.29%)

Earnings
Synlogic Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 04, 2021
Q3 2020 Synlogic Inc Earnings Call Transcript
Nov 05, 2020

$30 (+6.38%)

Earnings
Q2 2020 Synlogic Inc Earnings Call Transcript
Aug 06, 2020

$32.55 (-6.87%)

Earnings
Synlogic Inc Annual Shareholders Meeting Transcript
Jun 04, 2020
Synlogic Inc To Host Virtual R&D Event Transcript
May 27, 2020
Q1 2020 Synlogic Inc Earnings Call Transcript
May 08, 2020

$32.7 (-2.68%)

Earnings
Q4 2019 Synlogic Inc Earnings Call Transcript
Mar 12, 2020

$20.85 (-9.74%)

Earnings
Q3 2019 Synlogic Inc Earnings Call Transcript
Nov 12, 2019

$33.3 (-1.55%)

Earnings
Q2 2019 Synlogic Inc Earnings Call Transcript
Aug 08, 2019

$75 (+5.26%)

Earnings
Synlogic Inc Corporate Update Transcript
Jul 15, 2019
Synlogic Inc and Ginkgo Bioworks Inc to Discuss Collaboration for the Accelerated Development of Novel Synthetic Biotic™ Medicines Conference Call Transcript
Jun 12, 2019
Q1 2019 Synlogic Inc Earnings Call Transcript
May 09, 2019

$123.9 (+0.12%)

Earnings
Q4 2018 Synlogic Inc Earnings Call Transcript
Mar 12, 2019

$116.1 (-7.86%)

Earnings

Synlogic Inc Clinical Program Update Call Transcript

Sep 20, 2021 / 12:30PM GMT

Release Date Price: $55.65 (+12.77%)

Transcript

Operator

Good morning. Welcome to Synlogic's Clinical Program Update Call. (Operator Instructions) Please be advised that this call is being recorded. I would now like to turn the call over to Daniel Rosan, Head of Finance and Investor Relations. Please proceed.

Daniel Rosan

Synlogic, Inc. - Senior VP, Head of Finance & IR

Thank you, operator. Good morning, everybody, and thank you for joining us on today's conference call. This morning, we issued a press release, which outlines progress in our phenylketonuria program and additional business updates. This release is available on the Investors section of our website at synlogictx.com.

Joining me this morning are Dr. Aoife Brennan, President and Chief Executive Officer; and Dr. David Hava, Chief Scientific Officer. Other members of the Synlogic management team will be available during the Q&A.

Before we begin, I'd like to remind everyone that comments today may include forward-looking statements made under the Private Securities Litigation Reform Act of 1995. These forward-looking statements

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.